Izervay: payments to doctors
Payments that named Izervay as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.4M
- Providers
- 6,613
- Transactions
- 19,548
- Average per transaction
- $275
The per-transaction average — $275 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,613 providers the average total is $812, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astellas Pharma US Inc | $4,817,125 | 89.7% |
| Astellas Pharma Global Development | $543,470 | 10.1% |
| Astellas Pharma Europe Ltd | $8,448 | 0.2% |
| Astellas US LLC | $1,600 | 0.0% |